REGEN-COV(®) antibody cocktail bioanalytical strategy: comparison of LC-MRM-MS and immunoassay methods for drug quantification

Aim: In response to the COVID-19 pandemic, Regeneron developed the anti-SARS-CoV-2 monoclonal antibody cocktail, REGEN-COV(®) (RONAPREVE(®) outside the USA). Drug concentration data was important for determination of dose, so a two-part bioanalytical strategy was implemented to ensure the therapy wa...

Descripción completa

Detalles Bibliográficos
Autores principales: Irvin, Susan C, Ganguly, Samit, Weiss, Rachel, Elango, Chinnasamy, Zhong, Xuefei, Mao, Yuan, Yan, Hong, Li, Ning, Sumner, Giane, Turner, Kenneth C, Davis, John D, DiCioccio, A Thomas, Andisik, Matthew D, Partridge, Michael A, Torri, Albert
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Newlands Press Ltd 2021
Materias:
Bioanalytical Challenge
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8579949/
https://www.ncbi.nlm.nih.gov/pubmed/34743612
http://dx.doi.org/10.4155/bio-2021-0190

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8579949/
https://www.ncbi.nlm.nih.gov/pubmed/34743612
http://dx.doi.org/10.4155/bio-2021-0190

Ejemplares similares